Pharmacokinetics, safety, efficacy and immunogenicity of Adalimumab biosimilar ABP-501in rheumatoid arthritis and plaque psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2021.
Autor principal: | Akter, Anika |
---|---|
Altres autors: | Alam, Marzia |
Format: | Thesis |
Idioma: | English |
Publicat: |
Brac University
2022
|
Matèries: | |
Accés en línia: | http://hdl.handle.net/10361/17039 |
Ítems similars
-
Biologics and Biosimilars as Treatment Options for Psoriasis
per: Moya, Amena Khatun
Publicat: (2023) -
Importance of biologics in rheumatoid arthritis management
per: Riyadh, S. M.
Publicat: (2022) -
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
per: Afroza, Halima
Publicat: (2024) -
Importance of biologically active agents over other therapies in Rheumatoid Arthritis- a review
per: Mehreen, Elnaj
Publicat: (2021) -
A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
per: Islam, Nahidul
Publicat: (2023)